Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]

Figure 1

Computed tomography scan during the interferon treatment. Computed tomography scan, performed after the 20th week for DD/DI patient (left) and during the 52nd week for HDI patient (right), confirmed mild ground-glass opacities in both lungs with bronchial wall and interstitial thickening. Sputum cultures were negative for bacteria, fungi, and acid-fast bacilli.

Back to article page
\